Research and Markets: Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity and Applications

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/a89f59/handbook_of_harnes) has announced the addition of the "Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity and Applications" book to their offering.

Nanomedicine has emerged as a novel field in medicine integrating nano-scale technologies with materials sciences, chemistry and biology. The medical application of nanotechnology has the potential to revolutionize diagnosis and therapy and bring this new field from a notion into reality while impacting the lives of millions around the world.

This book compiles and details cutting-edge research in science and medicine from the interdisciplinary standpoint who are currently revolutionizing drug delivery techniques through the development of nanomedicines. Edited by Dan Peer, a prominent bio-nanotechnologiest, this book will attract anyone involved materials sciences, chemistry, biology and medicine that would like to design applications in the medical field of nanotechnology towards cancer therapy, inflammation, viral infection, imaging and toxicity.

Key Features:

  • Covers research on various aspects of nanomedicine, including aspects from chemistry, biology, various diagnostic methodologies, RNAi as a new class of nanomedicines and two special contributions of immuno-nano-toxicity.
  • Includes contributions from several world experts in immuno-nanotoxicity, top researchers from Harvard and Yale, and from the co-inventor of the first particulate nanomedicine (Pegylated liposomal doxorubicin - DOXIL)
  • Illustrated throughout with excellent figures and references to accompany each section.

Readership:

Advanced undergraduate-and graduate-level students in nanotechnology; researchers in macromolecular science, nanotechnology, chemistry, biology, and medicine, especially those with an interest in drug delivery; cancer therapy, inflammation, RNAi, imaging with nanocarriers, and immuno-nanotoxicity.

Author:

Dan Peer is a principal investigator and a senior lecturer that leads an NIH-funded laboratory at Tel Aviv University.

For more information visit http://www.researchandmarkets.com/research/a89f59/handbook_of_harnes



CONTACT:

Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:

INDUSTRY KEYWORDS:   Health  Biotechnology

MEDIA:

Logo
 Logo

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.